We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pediatric FN Definition 2012 Bern

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01683370
First Posted: September 11, 2012
Last Update Posted: April 28, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Swiss Cancer League
Information provided by (Responsible Party):
Roland A. Ammann, Swiss Pediatric Oncology Group
  Purpose

STUDY AIMS Based on prospectively collected information on ear temperatures, ANC values, emergency calls and consultations for fever, and on hospitalizations for FN in children and adolescents with cancer

  • to describe the frequency of episodes of FN, and of other clinically relevant FN-related measures
  • to compare these frequencies and measures in reality vs. applying Bernese standard limits for defining fever (ear temperature ≥39.0°C)
  • to compare these frequencies and measures applying the Bernese standard limit of ≥39.0°C (LimitStandard) vs. a range of hypothetically lower limits defining fever (LimitLow)
  • to determine if it would be useful to perform an interventional study on the question of different fever limits, powered to study both efficacy (frequency of FN) and safety (AE in delayed FN diagnosis)
  • to use the platform of this prospective study to explore if the serum level of cortisol is associated with adverse events in FN

HYPOTHESIS In children and adolescents with cancer, hypothetically modifying the definitions of fever from ear temperature 39.0°C to lower limits would

  • increase the rate of FN episodes diagnosed during chemotherapy (primary endpoint).
  • increase the rate of other clinically important FN-related measures related to chemotherapy exposure time (secondary endpoints 1,2,3) and outcome/treatment-related measures during treatment of FN episodes diagnosed in reality (secondary endpoints 4,5,6).
  • not relevantly decrease the proportion of FN with AE (secondary endpoint 7).

Condition
Cancer in Children/Adolescents Fever in Neutropenia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Pediatric FN Definition 2012 Bern The Impact of Lowering Fever Limits on the Rate of Fever in Chemotherapy-induced Neutropenia (FN). A Prospective Single-center Observational Study in Children and Adolescents With Cancer.

Resource links provided by NLM:


Further study details as provided by Roland A. Ammann, Swiss Pediatric Oncology Group:

Primary Outcome Measures:
  • Rate ratio of additional episodes of FN diagnosed (applying LimitLow vs. LimitStandard) [ Time Frame: until 2 weeks after last dose of chemotherapy (expected median, 6 months) ]

Secondary Outcome Measures:
  • Rate of episodes of fever [ Time Frame: until 2 weeks after last dose of chemotherapy (expected median, 6 months) ]
    (Protocol: 1)

  • Rate of emergency calls for fever [ Time Frame: until 2 weeks after last dose of chemotherapy (expected median, 6 months) ]
    (Protocol: 2a)

  • Rate ratio of FN diagnosed earlier (applying LimitLow vs. LimitStandard) [ Time Frame: until 2 weeks after last dose of chemotherapy (expected median, 6 months) ]
    (Protocol: 3)

  • Proportion of FN with blood cultures performed after start of antibiotics (AB) for prolonged fever [ Time Frame: until end of AB therapy for FN (estimated median, 4 days) ]
    (Protocol: 4a)

  • Proportion of FN with delayed hospital discharge for prolonged fever [ Time Frame: until end of AB therapy for FN (estimated median, 4 days) ]
    (Protocol: 5) (Low risk FN episodes with first-day stepping down will be excluded from this analysis.)

  • Time point of empirical AB switch for prolonged fever during FN [ Time Frame: until end of AB therapy for FN (estimated median, 4 days) ]
    (Protocol: 6a)

  • Proportion of FN with any adverse event [ Time Frame: until end of AB therapy for FN (estimated median, 4 days) ]
    (Protocol: 7a)

  • Serum level of cortisol [ Time Frame: at presentation with FN (in reality) ]
    (Protocol: 8)

  • Proportion of FN with switch of empirical AB for prolonged fever [ Time Frame: until end of AB therapy for FN (estimated median, 4 days) ]
    (Protocol: 4b)

  • Proportion of FN with add-on of empirical antifungal therapy for prolonged fever [ Time Frame: until end of AB therapy for FN (estimated median, 4 days) ]
    (Protocol: 4c)

  • Rate of emergency CBC with consultation for fever [ Time Frame: until 2 weeks after last dose of chemotherapy (expected median, 6 months) ]
    (Protocol: 2b)

  • Time point of starting empirical antifungal therapy for prolonged fever during FN [ Time Frame: until end of AB therapy for FN (estimated median, 4 days) ]
    (Protocol: 6b)

  • Proportion of FN with bacteremia [ Time Frame: until end of AB therapy for FN (estimated median, 4 days) ]
    (Protocol: 7b)

  • Proportion of FN with serious medical complication [ Time Frame: until end of AB therapy for FN (estimated median, 4 days) ]
    (Protocol: 7c)


Biospecimen Retention:   Samples Without DNA
1 mL serum, kept refrigerated until the end of study, then analyed as batch for cortisol, then discarded.

Enrollment: 39
Study Start Date: August 2012
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
Patients
Pediatric patients with cancer, receiving standard chemotherapy, and receiving standard supportive therapy in case of fever in neutropenia (FN) (No intervention for study purposes)

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Pediatric patients diagnosed with cancer requiring chemotherapy, treated at the Division of Pediatric Hematology/Oncology, Department of Pediatric, University of Bern / Inselspital, CH-3010 Bern, Switzerland
Criteria

Inclusion Criteria:

  • >1 year and ≤17 years at time of recruitment
  • Chemotherapy treatment because of any malignancy for at least 2 months at time of recruitment
  • Written informed consent from patients and/or parents for the study

Exclusion Criteria:

  • Infants ≤1 year old (reason: differences in standard fever limit and method to measure temperature)
  • Denied written informed consent from patients and/or parents for the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01683370


Locations
Switzerland
Division of Hematology/Oncology, Department of Pediatrics, University of Bern / Inselspital
Bern, Switzerland, CH-3010
Sponsors and Collaborators
Roland A. Ammann
Swiss Cancer League
Investigators
Study Chair: Roland A Ammann, MD Pediatric Hematology/Oncology, Department of Pediatrics, University of Bern, Bern, Switzerland
  More Information

Publications:
Responsible Party: Roland A. Ammann, Associate Professor, Swiss Pediatric Oncology Group
ClinicalTrials.gov Identifier: NCT01683370     History of Changes
Other Study ID Numbers: PFND2012B
KFS-2933-02-2012 ( Other Grant/Funding Number: Krebsforschung Schweiz )
First Submitted: August 31, 2012
First Posted: September 11, 2012
Last Update Posted: April 28, 2016
Last Verified: April 2016

Additional relevant MeSH terms:
Fever
Neutropenia
Body Temperature Changes
Signs and Symptoms
Agranulocytosis
Leukopenia
Leukocyte Disorders
Hematologic Diseases